OS THERAPIES INCORPORATED
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-28.8M | $-8.9M | $-7.8M |
| Depreciation & Amortization | $363.1K | $2.8K | — |
| Depreciation | — | $2.8K | $4.2K |
| Amortization | — | — | — |
| Stock-Based Compensation | $4.3M | $268.3K | — |
| Net Cash from Operating Activities | $-14.2M | $-7.3M | $-3.0M |
| Investing Activities | |||
| Capital Expenditures | $466.4K | — | — |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-466.4K | — | $1.1K |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $9.4M | $12.8M | $2.9M |
| Net Change in Cash | — | — | — |
| Free Cash Flow | $-14.7M | — | — |